Genotyping as a tool to predict adverse drug reactions.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Current Topics in Medicinal Chemistry

• Publication date

  2004-08-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/1568026043387791PMID 15379654
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical Relevance and Management of Drug‐Related QT Interval Prolongation

  2003cited by this paper
• Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers.

  2003cited by this paper
• Exposure‐Dependent Inhibition of Intestinal and Hepatic CYP3A4 In Vivo by Grapefruit Juice

  2003cited by this paper
• Large-scale genotyping by mass spectrometry: experience, advances and obstacles.

  2002cited by this paper
• Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene.

  2002cited by this paper
• Genotyping of Drug Targets

  2002cited by this paper
• Differing effects of methylenetetrahydrofolate reductase single nucleotide polymorphisms on methotrexate efficacy and toxicity in rheumatoid arthritis.

  2002cited by this paper
• Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

  2002cited by this paper
• QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients

  2002cited by this paper
• Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol‐associated adverse effects

  2002cited by this paper
• Polymorphism of the N‐acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug–induced hepatitis

  2002cited by this paper
• Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.

  2002cited by this paper
• Abnormal Movements and Tardive Dyskinesia in Smokers and Nonsmokers with Schizophrenia Genotyped for Cytochrome P450 2D6

  2002cited by this paper
• Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses.

  2002cited by this paper
• Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.

  2002cited by this paper
• St John's wort (Hypericum perforatum): drug interactions and clinical outcomes.

  2002cited by this paper
• Genome complexity reduction for SNP genotyping analysis

  2002cited by this paper
• Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.

  2001cited by this paper
• Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.

  2001cited by this paper
• Severe phenytoin intoxication in a subject homozygous for CYP2C9*3

  2001cited by this paper
• Genetic susceptibility to adverse drug reactions.

  2001cited by this paper
• A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms

  2001cited by this paper
• Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia.

  2001cited by this paper
• TNFα promoter region gene polymorphisms in carbamazepine-hypersensitive patients

  2001cited by this paper
• Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism.

  2001cited by this paper
• Pharmacogenetics and cancer therapy

  2001cited by this paper
• Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine.

  2001cited by this paper
• CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants:
a first step towards subpopulation‐specific dosages

  2001cited by this paper
• Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy

  2001cited by this paper
• Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia

  2001cited by this paper
• Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity.

  2000cited by this paper
• Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.

  2000cited by this paper
• Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication.

  2000cited by this paper
• Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness.

  2000cited by this paper
• Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility

  2000cited by this paper
• Pharmacogenetics and adverse drug reactions.

  2000cited by this paper
• CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients

  2000cited by this paper
• Glucuronidation in Humans

  1999cited by this paper
• Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele.

  1999cited by this paper
• Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.

  1999cited by this paper
• Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil.

  1999cited by this paper
• Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.

  1999cited by this paper
• Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia

  1999cited by this paper
• Low penetrance in the long-QT syndrome: clinical impact.

  1999cited by this paper
• Association of the MscI Polymorphism of the Dopamine D3 Receptor Gene with Tardive Dyskinesia in Schizophrenia

  1999cited by this paper
• Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes

  1999cited by this paper
• Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis.

  1999cited by this paper
• Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.

  1998cited by this paper
• High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives.

  1998cited by this paper
• Predicting Effective Drug Concentrations for Individual Patients

  1998cited by this paper
• The arylamine N-acetyltransferase (NAT2) polymorphism and the risk of adverse reactions to co-trimoxazole in children

  1998cited by this paper
• Molecular Diagnosis of Thiopurine S-Methyltransferase Deficiency: Genetic Basis for Azathioprine and Mercaptopurine Intolerance

  1997cited by this paper
• Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients

  1997cited by this paper
• Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients

  1997cited by this paper
• Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity.

  1997cited by this paper
• Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine.

  1997cited by this paper
• Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors

  1997cited by this paper
• Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.

  1996cited by this paper
• Factor V Leiden: should we screen oral contraceptive users and pregnant women?

  1996cited by this paper
• Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias

  1996cited by this paper
• Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia.

  1995cited by this paper
• The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity.

  1995cited by this paper
• Geographical/Interracial Differences in Polymorphic Drug Oxidation

  1995cited by this paper
• SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome.

  1995cited by this paper
• Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency.

  1995cited by this paper
• A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome.

  1995cited by this paper
• A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome.

  1995cited by this paper
• Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation.

  1994cited by this paper
• Acetylation phenotype and cutaneous hypersensitivity to trimethoprim‐sulphamethoxazole in HIV‐infected patients

  1994cited by this paper
• Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient.

  1993cited by this paper
• The role of the skeletal muscle ryanodine receptor gene in malignant hyperthermia.

  1992cited by this paper
• Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia.

  1991cited by this paper
• The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects.

  1990cited by this paper
• Diagnosis of susceptibility to malignant hyperthermia in man.

  1988cited by this paper
• Aetiology of malignant hyperthermia.

  1988cited by this paper
• Polymorphic metabolism of the beta-adrenoreceptor blocking drugs and its clinical relevance.

  1985cited by this paper
• Impaired oxidation of debrisoquine in patients with perhexiline liver injury.

  1984cited by this paper

• Incidence and Severity of Adverse Drug Reactions in Medical Intensive Care Unit.

  2023cites this paper
• Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis

  2019cites this paper
• One-step isothermal detection of multiple KRAS mutations by forming SNP specific hairpins on a gold nanoshell.

  2018cites this paper
• Innovative biomarkers in psychiatric disorders: a major clinical challenge in psychiatry

  2017cites this paper
• Pharmacogenetics of neurological and psychiatric diseases at older age: has the time come?

  2017cites this paper
• The pharmacogenetic road to avoid adverse drug reactions and therapeutic failures in revolving door patients with psychiatric illnesses: focus on the CYP2D6 isoenzymes

  2016cites this paper
• The CYP4502D6 *4 and *6 alleles are the molecular genetic markers for drug response: implications in colchicine non-responder FMF patients

  2016cites this paper
• Psychiatry meets pharmacogenetics for the treatment of revolving door patients with psychiatric disorders

  2016cites this paper
• Pharmacogenetics in Neurodegenerative Diseases: Implications for Clinical Trials.

  2016cites this paper
• PCR free multiple ligase reactions and probe cleavages for the SNP detection of KRAS mutation with attomole sensitivity.

  2016cites this paper
• To translate pharmacogenetics in geriatrics: towards a personalized medicine

  2015cites this paper
• Measuring pharmacogenetics in special groups: geriatrics

  2015cites this paper
• New insights into the use of currently available non-steroidal anti-inflammatory drugs

  2015influential citation
• Variability in the response to non-steroidal anti-inflammatory drugs: mechanisms and perspectives.

  2014cites this paper
• Systematic Functional Study of Cytochrome P450 2D6 Promoter Polymorphisms in the Chinese Han Population

  2013cites this paper
• Genetic polymorphism of CYP2D6 gene among Egyptian hypertensive cases

  2013cites this paper
• Detection of SNP-containing human DNA sequences using a split sensor with a universal molecular beacon reporter.

  2013cites this paper
• A tripartile biosensor for real-time SNSs detection in DNA hairpin motif

  2011cites this paper
• Pharmacogenetics in geriatric medicine: challenges and opportunities for clinical practice.

  2011cites this paper
• Polimorfismos em CYP2E1, GSTM1 e GSTT1 e hepatotoxicidade no tratamento da tuberculose

  2010cites this paper
• Real-time SNP analysis in secondary-structure-folded nucleic acids.

  2010cites this paper
• Pharmacogenetics of cytochrome P450 (CYP) in the elderly.

  2010cites this paper
• A Single Molecular Beacon Probe Is Sufficient for the Analysis of Multiple Nucleic Acid Sequences

  2010cites this paper
• Can the genotype or phenotype of two polymorphic drug metabolising cytochrome P450-enzymes identify oral lichenoid drug eruptions?

  2010cites this paper
• Recent patents and challenges on DNA microarray probe design technologies.

  2010cites this paper
• P450 biochips : development of a protein microarray platform for investigating cytochrome P450 clinical drug metabolism

  2010cites this paper
• Untersuchungen zur Herstellung und Funktionalität neuartiger Padlock-Sonden für den Nukleinsäurenachweis auf Mikroarrays

  2010cites this paper
• Binary probes for nucleic acid analysis.

  2010cites this paper
• Analysis of single nucleotide polymorphisms using molecular affinity separation and mass spectrometry

  2009cites this paper
• Triple‐Stem DNA Probe: A New Conformationally Constrained Probe for SNP Typing

  2009cites this paper
• The plasma proteome, adductome and idiosyncratic toxicity in toxicoproteomics research.

  2008cites this paper
• Systematic polymorphism analysis of the CYP2D6 gene in four different geographical Han populations in mainland China.

  2008cites this paper
• Building effective institutional frameworks to support pharmacogenetic research: an international empirical analysis

  2008cites this paper
• A systematic genetic polymorphism analysis of the CYP2C9 gene in four different geographical Han populations in mainland China.

  2008cites this paper
• Applications of Quadrupole Time‐of‐Flight Mass Spectrometry in Reactive Metabolite Screening

  2008cites this paper
• enetic Susceptibility to Nonsteroidal Anti-Inflammatory Drug – Related astroduodenal Bleeding : Role of Cytochrome P 450 2 C 9 Polymorphisms

  2007influential citation
• Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.

  2007cites this paper
• SNP genotyping: technologies and biomedical applications.

  2007cites this paper
• Use of pairwise marker combination and recursive partitioning in a pharmacogenetic genome-wide scan

  2007cites this paper
• Application of TDM, pharmacogenomics and biomarkers for neurological disease pharmacotherapy: focus on antiepileptic drugs.

  2006cites this paper
• Risk Factors for Extrapyramidal Symptoms During Treatment With Selective Serotonin Reuptake Inhibitors, Including Cytochrome P-450 Enzyme, and Serotonin and Dopamine Transporter and Receptor Polymorphisms

  2006influential citation
• CYP2D6 genetic polymorphism in South Indian populations.

  2006cites this paper
• Bioinformatics in Drug Development and Assessment

  2005cites this paper
• A high-throughput liquid chromatography/tandem mass spectrometry method for screening glutathione conjugates using exact mass neutral loss acquisition.

  2005cites this paper
• Pharmakogenetik: Stand und Perspektiven

  2005cites this paper